Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • HC Wainwright reaffirms “Buy” rating with a USD 45.00 target on COMPASS Pathways (NASDAQ: CMPS)
  • Average analyst price target stands at USD 17.00, reflecting wide disparity in market outlooks
  • CMPS forecasts remain in negative earnings territory through FY2028, with profitability projected in FY2029

COMPASS Pathways plc (NASDAQ: CMPS), a clinical-stage mental health care company, received renewed attention from analysts this week after HC Wainwright reaffirmed its “Buy” rating on the stock. The firm maintained its ambitious price target of USD 45.00, based on expectations surrounding the development of COMP360, the company’s investigational psilocybin therapy for treatment-resistant depression (TRD) and other mental health conditions.

In its updated coverage, HC Wainwright also provided a detailed earnings outlook. The firm forecasts continued quarterly losses through 2026, with estimates for Q2–Q4 FY2025 ranging from (USD 0.38) to (USD 0.35) per share. The projection for FY2025 stands at a net loss of USD 1.55 per share. That negative trend is expected to persist into FY2026, with a projected loss of USD 1.62 per share. Profitability, however, is expected by FY2029, with an estimated EPS of USD 1.59.

Other brokerages remain more cautious. Evercore ISI reiterated an “In-line” rating on June 23, significantly lowering its price target from USD 11.00 to USD 6.00. Cantor Fitzgerald, meanwhile, reaffirmed its “Overweight” rating with a USD 12.00 target. Overall, MarketBeat data indicates that among seven analysts, six have rated the stock a “Buy” while one assigned a “Hold,” producing an average consensus rating of “Moderate Buy.” The average 12-month price target across all firms stands at USD 17.00, suggesting divergent views on CMPS's valuation potential.

COMPASS Pathways is currently advancing its lead candidate, COMP360, through Phase III trials for TRD and Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. Despite the speculative nature of biotech development and long timelines to profitability, analysts bullish on CMPS cite its differentiated approach in a high-need therapeutic category.